CClinicalTrials.gg
CompletedNCT05727436Updated Jun 23, 2023

The Effect of Probiotics on Gingivitis

An interventional study of Dentoblis and Placebo in Gingivitis; Chronic, sponsored by I.M. Sechenov First Moscow State Medical University. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by I.M. Sechenov First Moscow State Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

The aim of the study is to assess the effect of oral probiotics containing Streptococcus salivarius M18 on gingivitis and oral hygiene in young adults.

Read the detailed description

This will be a double-blind, randomized, placebo-controlled two-arm parallel-group study of the effect of oral probiotics containing Streptococcus salivarius M18 on gingivitis and oral hygiene. The groups will include young adults with gingivitis diagnosed clinically. To assess the effect of oral probiotics, the following parameters will be used: gingival index, GI; gingival bleeding index, GBI and oral hygiene level (the Turesky Modification of the Quigley-Hein Plaque Index, TMQHPI).

02

Conditions studied

  • Gingivitis; Chronic

Browse trials for

03

In context

Gingivitis

590 studies on the registry are indexed under Gingivitis; 104 are open to participants now.

This study's enrollment of 61 is close to the median of 64 across 478 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

I.M. Sechenov First Moscow State Medical University is the lead sponsor of 133 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged between 18-25 years
  • Permanent bite;
  • Presence of more than 20 teeth;
  • Absence of systemic and chronic diseases;
  • The diagnosis of gingivitis stated clinically.

Exclusion criteria

Exclusion Criteria:

  • Presence of mild, moderate or severe chronic periodontitis;
  • Refusal to sign informed consent;
  • Taking supplements and medication containing probiotics or prebiotics 1 months before the study;
  • Taking antibiotics (within 3 months before the study);
  • Allergy to the components of the drugs used in the study;
  • Presence of immunodeficiency, taking immunosuppressants.
  • Use of other hygiene products, immunostimulants and antibacterials, probiotics, prebiotics during the study;
  • Refusal to take a given medication;
  • Failure to attend check-ups.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Group 1 - probiotic

    Experimental: Group 1 - probiotic The use of Streptococcus salivarius M18 containing tablets ("Dentoblis", registration number: AM.01.06.01.003.R.000061.07.20; 15.07.2020, MEDICO DOMUS, d.d.o.; 18116, Nis, Serbia)) once a day for 4 weeks (before bedtime after evening brushing). Ingredients: basic active ingredients - Streptococcus salivarius M18 (≥5×108 CFU in 1 tablet), Vitamin D (320 IU (8 mcg) in 1 tablet); excipients - isomalt (sweetener), magnesium stearate (vegetable), mint flavoring.

    Dietary Supplement: Dentoblis

  • Placebo comparator
    Group 2 - placebo

    The use of placebo tablets once a day for 4 weeks (before bedtime after evening brushing). Ingredients: isomalt (sweetener), magnesium stearate (vegetable), mint flavoring.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementDentoblis

    Dissolve the tablets in the mouth once a day for 4 weeks

    Also known as: Probiotic: Streptococcus salivarius M18

  • Dietary supplementPlacebo

    Dissolve the tablets in the mouth once a day for 4 weeks

06

What researchers measure

Primary outcomes

  1. Evaluation of gingival inflammation using Gingival Index (GI) by H. Loe and J. Silness

    GI is used to assess visual symptoms of gingivitis on mesial, distal, vestibular, and oral areas of each scorable tooth (1.6, 1.2, 2.4, 3.6, 3.2, 4.4). Each area is given a score from 0 to 3. Values are presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e., 0-3). Scoring is performed using standard dental light: 0 = absence of inflammation; 1 = mild inflammation - slight change in color and little change in texture; 2 = moderate inflammation - moderate glazing, redness, oedema, and hypertrophy, bleeding on pressure; 3 = severe inflammation - marked redness and hypertrophy, tendency to spontaneous bleeding, ulceration. Lower scores indicate better results.

    Time frame: 4 weeks after the baseline

  2. Evaluation of gingival inflammation using Gingival Index (GI) by H. Loe and J. Silness

    GI is used to assess visual symptoms of gingivitis on mesial, distal, vestibular, and oral areas of each scorable tooth (1.6, 1.2, 2.4, 3.6, 3.2, 4.4). Each area is given a score from 0 to 3. Values are presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e., 0-3). Scoring is performed using standard dental light: 0 = absence of inflammation; 1 = mild inflammation - slight change in color and little change in texture; 2 = moderate inflammation - moderate glazing, redness, oedema, and hypertrophy, bleeding on pressure; 3 = severe inflammation - marked redness and hypertrophy, tendency to spontaneous bleeding, ulceration. Lower scores indicate better results.

    Time frame: 8 weeks after the baseline

  3. Evaluation of gingival inflammation using Gingival bleeding index (GBI) by J. Ainamo and I. Bay, 1975

    GBI is used to assess bleeding elicited on probing as a measure of gingival condition. Gingivae are air dried and examiner assesses bleeding using a probe which is gently inserted into gingival crevice to depth of app 1 mm and run around tooth (angle of app 60 deg to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI is assessed on mesial, distal, vestibular, and oral areas of each scorable tooth (whole mouth). Values are presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e., 0-1). BI score:0=no bleeding after 10 sec, 1=bleeding upon probing after 10 sec or immediate bleeding. Lower scores indicate better results.

    Time frame: 4 weeks after the baseline

  4. Evaluation of gingival inflammation using Gingival bleeding index (GBI) by J. Ainamo and I. Bay, 1975

    GBI is used to assess bleeding elicited on probing as a measure of gingival condition. Gingivae are air dried and examiner assesses bleeding using a probe which is gently inserted into gingival crevice to depth of app 1 mm and run around tooth (angle of app 60 deg to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI is assessed on mesial, distal, vestibular, and oral areas of each scorable tooth (whole mouth). Values are presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e., 0-1). BI score:0=no bleeding after 10 sec, 1=bleeding upon probing after 10 sec or immediate bleeding. Lower scores indicate better results.

    Time frame: 8 weeks after the baseline

Secondary outcomes

  1. Evaluation of oral hygiene using Turesky Modification of the Quigley-Hein Plaque Index

    A plaque detection solution is used to detect the presence of plaque on both the vestibular and oral surfaces of all teeth except the third molars. Each surface is divided into 3 segments: mesial, central and distal. Thus, 6 segments are evaluated for each tooth. Evaluation criteria: 0 - no staining; 1. - separate areas of plaque in the cervical part; 2. - plaque in the form of a thin continuous band up to 1 mm wide in the cervical part; 3. - cervical part is covered by plaque that is more than 1 mm wide, but less than 1/3 of the tooth crown; 4. - plaque covers 1/3 to 2/3 of the crown; 5. - plaque covers more than 2/3 of the crown.

    Time frame: 4 weeks after the baseline

  2. Evaluation of oral hygiene using Turesky Modification of the Quigley-Hein Plaque Index

    A plaque detection solution is used to detect the presence of plaque on both the vestibular and oral surfaces of all teeth except the third molars. Each surface is divided into 3 segments: mesial, central and distal. Thus, 6 segments are evaluated for each tooth. Evaluation criteria: 0 - no staining; 1. - separate areas of plaque in the cervical part; 2. - plaque in the form of a thin continuous band up to 1 mm wide in the cervical part; 3. - cervical part is covered by plaque that is more than 1 mm wide, but less than 1/3 of the tooth crown; 4. - plaque covers 1/3 to 2/3 of the crown; 5. - plaque covers more than 2/3 of the crown.

    Time frame: 8 weeks after the baseline

07

Study locations

1 site
  • Institute of Dentistry of Sechenov University
    Moscow, 121059, Russian Federation
08

References and documents

Publications

  • Babina K, Salikhova D, Polyakova M, Svitich O, Samoylikov R, Ahmad El-Abed S, Zaytsev A, Novozhilova N. The Effect of Oral Probiotics (Streptococcus Salivarius k12) on the Salivary Level of Secretory Immunoglobulin A, Salivation Rate, and Oral Biofilm: A Pilot Randomized Clinical Trial. Nutrients. 2022 Mar 7;14(5):1124. doi: 10.3390/nu14051124. PubMed 35268099 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05727436
Lead sponsor
I.M. Sechenov First Moscow State Medical University
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Feb 20, 2023
Primary completion
May 31, 2023
Completion
May 31, 2023
Last update
Jun 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion